Regeneron Pharmaceuticals, Inc.
REGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000872589
In the last 90 days, Regeneron Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 1,342 institutions reported holding it in 13F filings for Q2 2026, worth $57.1B in total; Southeastern Asset Management (Longleaf) is the only superinvestor holding it.
13F holders, Q1 2023
Institutional positions in Regeneron Pharmaceuticals, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,196
- +50 vs. Q4 2022
- Shares held
- 99.1M
- +5.03M (+5.3%) vs. Q4 2022
- Total value
- $76.1B
- +$9.34B (+14.0%) vs. Q4 2022
- New holders
- 131
- 442 more added
- Sold out
- 81
- 422 more reduced
15 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting REGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,342 | $57.1B |
| Q1 2026 | 1,401 | $69.8B |
| Q4 2025 | 1,387 | $70.7B |
| Q3 2025 | 1,243 | $49.0B |
| Q2 2025 | 1,201 | $46.9B |
| Q1 2025 | 1,290 | $59.0B |
| Q4 2024 | 1,320 | $66.6B |
| Q3 2024 | 1,393 | $97.5B |
| Q2 2024 | 1,335 | $98.9B |
| Q1 2024 | 1,313 | $89.3B |
| Q4 2023 | 1,274 | $80.3B |
| Q3 2023 | 1,180 | $75.1B |
| Q2 2023 | 1,168 | $66.2B |
| Q1 2023 | 1,196 | $76.1B |
| Q4 2022 | 1,161 | $66.9B |
| Q3 2022 | 1,081 | $64.0B |
| Q2 2022 | 1,066 | $55.0B |
| Q1 2022 | 1,097 | $64.5B |
| Q4 2021 | 1,081 | $56.9B |
| Q3 2021 | 1,022 | $54.5B |
| Q2 2021 | 975 | $49.6B |
| Q1 2021 | 926 | $42.3B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Regeneron Pharmaceuticals, Inc.; share changes are against Q4 2022.